Low dose irradiation of thyroid cells reveals a unique transcriptomic and epigenetic signature in RET/PTC-positive cells

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 731, Issue 1-2, 2012, Pages 27-40

  Abou El Ardat, Khalil ^a,b   Monsieurs, Pieter ^a   Anastasov, Nataša ^c   Atkinson, Mike ^c   Derradji, Hanane ^a   De Meyer, Tim ^b   Bekaert, Sofie ^d   Van Criekinge, Wim ^b   Baatout, Sarah ^a,b  

^a BELGIAN NUCLEAR RESEARCH CENTRE   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

Micro RNA; RET PTC translocation; Thyroid; X irradiation, Low doses

Indexed keywords

MICRORNA; PROTEIN PATCHED; PROTEIN RET;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW ENERGY RADIATION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RADIATION EXPOSURE; RADIATION RESPONSE; SIGNAL TRANSDUCTION; THYROID CELL; THYROID WEIGHT; WILD TYPE;

ANIMALS; CELL LINE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED C57BL; MICRORNAS; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; RNA PROCESSING, POST-TRANSCRIPTIONAL; THYROID GLAND; THYROID NEOPLASMS; X-RAYS;

EID: 84856214659     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2011.10.006     Document Type: Article

References (78)

1. Blackburn D.J., Michel L.A., Rosiere A., Trigaux J.P., Donckier J.E. Occurrence of thyroid papillary carcinoma in young patients. A Chernobyl connection?. J. Pediatr. Endocrinol. Metab. 2001, 14:503-506.
2. Cardis E., Howe G., Ron E., Bebeshko V., Bogdanova T., Bouville A., Carr Z., Chumak V., Davis S., Demidchik Y., Drozdovitch V., Gentner N., Gudzenko N., Hatch M., Ivanov V., Jacob P., Kapitonova E., Kenigsberg Y., Kesminiene A., Kopecky K.J., Kryuchkov V., Loos A., Pinchera A., Reiners C., Repacholi M., Shibata Y., Shore R.E., Thomas G., Tirmarche M., Yamashita S., Zvonova I. Cancer consequences of the Chernobyl accident: 20 years on. J. Radiol. Prot. 2006, 26:127-140.
3. Hatch M., Ron E., Bouville A., Zablotska L., Howe G. The Chernobyl disaster: cancer following the accident at the Chernobyl nuclear power plant. Epidemiol. Rev. 2005, 27:56-66.
4. Knostman K.A., Jhiang S.M., Capen C.C. Genetic alterations in thyroid cancer: the role of mouse models. Vet. Pathol. 2007, 44:1-14.
5. Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557-563.
6. Santoro M., Dathan N.A., Berlingieri M.T., Bongarzone I., Paulin C., Grieco M., Pierotti M.A., Vecchio G., Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994, 9:509-516.
7. Besset V., Scott R.P., Ibanez C.F. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J. Biol. Chem. 2000, 275:39159-39166.
8. Chiariello M., Visconti R., Carlomagno F., Melillo R.M., Bucci C., de Franciscis V., Fox G.M., Jing S., Coso O.A., Gutkind J.S., Fusco A., Santoro M. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene 1998, 16:2435-2445.
9. Segouffin-Cariou C., Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J. Biol. Chem. 2000, 275:3568-3576.
10. Mizuno T., Iwamoto K.S., Kyoizumi S., Nagamura H., Shinohara T., Koyama K., Seyama T., Hamatani K. Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene 2000, 19:438-443.
11. Santoro M., Thomas G.A., Vecchio G., Williams G.H., Fusco A., Chiappetta G., Pozcharskaya V., Bogdanova T.I., Demidchik E.P., Cherstvoy E.D., Voscoboinik L., Tronko N.D., Carss A., Bunnell H., Tonnachera M., Parma J., Dumont J.E., Keller G., Hofler H., Williams E.D. Gene rearrangement and Chernobyl related thyroid cancers. Br. J. Cancer 2000, 82:315-322.
12. Port M., Boltze C., Wang Y., Roper B., Meineke V., Abend M. A radiation-induced gene signature distinguishes post-Chernobyl from sporadic papillary thyroid cancers. Radiat. Res. 2007, 168:639-649.
13. Detours V., Delys L., Libert F., Weiss Solis D., Bogdanova T., Dumont J.E., Franc B., Thomas G., Maenhaut C. Genome-wide gene expression profiling suggests distinct radiation susceptibilities in sporadic and post-Chernobyl papillary thyroid cancers. Br. J. Cancer 2007, 97:818-825.
14. Bonner W.M. Low-dose radiation: thresholds, bystander effects, and adaptive responses. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4973-4975.
15. Sadetzki S., Calderon-Margalit R., Modan B., Srivastava S., Tuttle R.M. Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external-beam irradiation in childhood. J. Clin. Endocrinol. Metab. 2004, 89:2281-2289.
16. Averbeck D. Does scientific evidence support a change from the LNT model for low-dose radiation risk extrapolation?. Health Phys. 2009, 97:493-504.
17. Jin Y.W., Na Y.J., Lee Y.J., An S., Lee J.E., Jung M., Kim H., Nam S.Y., Kim C.S., Yang K.H., Kim S.U., Kim W.K., Park W.Y., Yoo K.Y., Kim J.H. Comprehensive analysis of time- and dose-dependent patterns of gene expression in a human mesenchymal stem cell line exposed to low-dose ionizing radiation. Oncol. Rep. 2008, 19:135-144.
18. Amundson S.A., Do K.T., Shahab S., Bittner M., Meltzer P., Trent J., Fornace A.J. Identification of potential mRNA biomarkers in peripheral blood lymphocytes for human exposure to ionizing radiation. Radiat. Res. 2000, 154:342-346.
19. Kang C.M., Park K.P., Song J.E., Jeoung D.I., Cho C.K., Kim T.H., Bae S., Lee S.J., Lee Y.S. Possible biomarkers for ionizing radiation exposure in human peripheral blood lymphocytes. Radiat. Res. 2003, 159:312-319.
20. J.B. Smith, A. Nicholas, Chernobyl - Catastrophe and Consequences, Praxis Publishing Ltd., Chichester, 2005.
21. Sadetzki S., Chetrit A., Lubina A., Stovall M., Novikov I. Risk of thyroid cancer after childhood exposure to ionizing radiation for tinea capitis. J. Clin. Endocrinol. Metab. 2006, 91:4798-4804.
22. K. Abou-El-Ardat, H. Derradji, W. de Vos, T. de Meyer, S. Bekaert, W. van Criekinge, S. Baatout, Response to low-dose X-irradiation is p53-dependent in a papillary thyroid carcinoma model system, Int. J. Oncol. 39 (6) (2011) 1429-1441.
23. Santoro M., Chiappetta G., Cerrato A., Salvatore D., Zhang L., Manzo G., Picone A., Portella G., Santelli G., Vecchio G., Fusco A. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 1996, 12:1821-1826.
24. Powell D.J., Russell J., Nibu K., Li G., Rhee E., Liao M., Goldstein M., Keane W.M., Santoro M., Fusco A., Rothstein J.L. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 1998, 58:5523-5528.
25. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
26. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
27. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
28. Bolstad B.M., Irizarry R.A., Astrand M., Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.
29. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3:25.
30. Benjamini Y., Hochberg Y. Controlling the false discovery rate - A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B-Methodol. 1995, 57:289-300.
31. Lee M.L., Whitmore G.A. Power and sample size for DNA microarray studies. Stat. Med. 2002, 21:3543-3570.
32. Huang Y., Prasad M., Lemon W.J., Hampel H., Wright F.A., Kornacker K., LiVolsi V., Frankel W., Kloos R.T., Eng C., Pellegata N.S., de la Chapelle A. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:15044-15049.
33. Wasenius V.M., Hemmer S., Kettunen E., Knuutila S., Franssila K., Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin. Cancer Res. 2003, 9:68-75.
34. Jarzab B., Wiench M., Fujarewicz K., Simek K., Jarzab M., Oczko-Wojciechowska M., Wloch J., Czarniecka A., Chmielik E., Lange D., Pawlaczek A., Szpak S., Gubala E., Swierniak A. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005, 65:1587-1597.
35. Burniat A., Jin L., Detours V., Driessens N., Goffard J.C., Santoro M., Rothstein J., Dumont J.E., Miot F., Corvilain B. Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers. Endocrinology 2008, 149:5107-5117.
36. Thangaraju M., Gopal E., Martin P.M., Ananth S., Smith S.B., Prasad P.D., Sterneck E., Ganapathy V. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res. 2006, 66:11560-11564.
37. Gupta N., Martin P.M., Prasad P.D., Ganapathy V., SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci. 2006, 78:2419-2425.
38. Ganapathy V., Gopal E., Miyauchi S., Prasad P.D. Biological functions of SLC5A8, a candidate tumour suppressor. Biochem. Soc. Trans. 2005, 33:237-240.
39. Kim D.W., Chung H.K., Park K.C., Hwang J.H., Jo Y.S., Chung J., Kalvakolanu D.V., Resta N., Shong M. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). Mol. Endocrinol. 2007, 21:3039-3049.
40. Melillo R.M., Castellone M.D., Guarino V., De Falco V., Cirafici A.M., Salvatore G., Caiazzo F., Basolo F., Giannini R., Kruhoffer M., Orntoft T., Fusco A., Santoro M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 2005, 115:1068-1081.
41. Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 2007, 17:707-715.
42. Hieber L., Huber R., Bauer V., Schaffner Q., Braselmann H., Thomas G., Bogdanova T., Zitzelsberger H. Chromosomal rearrangements in post-Chernobyl papillary thyroid carcinomas: evaluation by spectral karyotyping and automated interphas FISH. J. Biomed. Biotechnol. 2011, 2011:693691.
43. Unger K., Malisch E., Thomas G., Braselmann H., Walch A., Jackl G., Lewis P., Lengfelder E., Bogdanova T., Wienberg J., Zitzelsberger H. Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC. Oncogene 2008, 27:4592-4602.
44. Finn S., Smyth P., O'Regan E., Cahill S., Toner M., Timon C., Flavin R., O'Leary J., Sheils O. Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines. Arch. Pathol. Lab. Med. 2007, 131:65-73.
45. Hu S., Liu D., Tufano R.P., Carson K.A., Rosenbaum E., Cohen Y., Holt E.H., Kiseljak-Vassiliades K., Rhoden K.J., Tolaney S., Condouris S., Tallini G., Westra W.H., Umbricht C.B., Zeiger M.A., Califano J.A., Vasko V., Xing M. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int. J. Cancer 2006, 119:2322-2329.
46. Martin C.L., Reshmi S.C., Ried T., Gottberg W., Wilson J.W., Reddy J.K., Khanna P., Johnson J.T., Myers E.N., Gollin S.M. Chromosomal imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of the literature. Oral Oncol. 2008, 44:369-382.
47. H. Kryh, H. Caren, J. Erichsen, R.M. Sjoberg, J. Abrahamsson, P. Kogner, T. Martinsson, Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors, BMC Genom. 12 (2011) 443.
48. Feys T., Poppe B., De Preter K., Van Roy N., Verhasselt B., De Paepe P., De Paepe A., Speleman F. A detailed inventory of DNA copy number alterations in four commonly used Hodgkin's lymphoma cell lines. Haematologica 2007, 92:913-920.
49. Zhang G., Wang G., Wang S., Li Q., Ouyang G., Peng X. Applying proteomic methodologies to analyze the effect of hexamethylene bisacetamide (HMBA) on proliferation and differentiation of human gastric carcinoma BGC-823 cells. Int. J. Biochem. Cell Biol. 2004, 36:1613-1623.
50. J. Hess, G. Thomas, H. Braselmann, V. Bauer, T. Bogdanova, J. Wienberg, H. Zitzelsberger, K. Unger, Gain of chromosome band 7q11 in papillary thyroid carcinomas of young patients is associated with exposure to low-dose irradiation, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 9595-9600.
51. Jin L., Burniat A., Dumont J.E., Miot F., Corvilain B., Franc B. Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice. Br. J. Cancer 2008, 99:1874-1883.
52. Karthigeyan D., Prasad S.B., Shandilya J., Agrawal S., Kundu T.K. Biology of aurora A kinase: Implications in cancer manifestation and therapy. Med. Res. Rev. 2011, 31:757-793.
53. Carmena M., Ruchaud S., Earnshaw W.C. Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins. Curr. Opin. Cell Biol. 2009, 21:796-805.
54. Lim S.K., Gopalan G. Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-A degradation through an alternative ubiquitin-independent pathway. Biochem. J. 2007, 403:119-127.
55. Yokoyama-Kobayashi M., Saeki M., Sekine S., Kato S. Human cDNA encoding a novel TGF-beta superfamily protein highly expressed in placenta. J. Biochem. 1997, 122:622-626.
56. Hotten G., Neidhardt H., Jacobowsky B., Pohl J. Cloning and expression of recombinant human growth/differentiation factor 5. Biochem. Biophys. Res. Commun. 1994, 204:646-652.
57. Yamaguchi K., Lee S.H., Eling T.E., Baek S.J. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J. Biol. Chem. 2004, 279:49617-49623.
58. Li P.X., Wong J., Ayed A., Ngo D., Brade A.M., Arrowsmith C., Austin R.C., Klamut H.J. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J. Biol. Chem. 2000, 275:20127-20135.
59. Bauskin A.R., Brown D.A., Kuffner T., Johnen H., Luo X.W., Hunter M., Breit S.N. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. 2006, 66:4983-4986.
60. M. Mimeault, S.K. Batra, Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer, J. Cell Physiol. 224 (2010) 626-635.
61. Yang H., Filipovic Z., Brown D., Breit S.N., Vassilev L.T. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol. Cancer Ther. 2003, 2:1023-1029.
62. Chen X. Cyclin G: a regulator of the p53-Mdm2 network. Dev. Cell 2002, 2:518-519.
63. Zhao L., Samuels T., Winckler S., Korgaonkar C., Tompkins V., Horne M.C., Quelle D.E. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. Mol. Cancer Res. 2003, 1:195-206.
64. S. D'Inzeo, A. Nicolussi, A. Ricci, P. Mancini, A. Porcellini, F. Nardi, A. Coppa, Role of reduced expression of SMAD4 in papillary thyroid carcinoma, J. Mol. Endocrinol. 45 (2010) 229-244.
65. Zhang D., Shimizu T., Araki N., Hirota T., Yoshie M., Ogawa K., Nakagata N., Takeya M., Saya H. Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice. Oncogene 2008, 27:4305-4314.
66. J.J. Huck, M. Zhang, A. McDonald, D. Bowman, K.M. Hoar, B. Stringer, J. Ecsedy, M.G. Manfredi, M.L. Hyer, MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo, Mol. Cancer Res. (2010) 8 373-384.
67. Kis E., Szatmari T., Keszei M., Farkas R., Esik O., Lumniczky K., Falus A., Safrany G. Microarray analysis of radiation response genes in primary human fibroblasts. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:1506-1514.
68. E. Huntzinger, E. Izaurralde, Gene silencing by microRNAs: contributions of translational repression and mRNA decay, Nat. Rev. Genet. 12 (2011) 99-110.
69. Israel A., Sharan R., Ruppin E., Galun E. Increased microRNA activity in human cancers. PLoS One 2009, 4:e6045.
70. Marsit C.J., Eddy K., Kelsey K.T. MicroRNA responses to cellular stress. Cancer Res. 2006, 66:10843-10848.
71. Simone N.L., Soule B.P., Ly D., Saleh A.D., Savage J.E., Degraff W., Cook J., Harris C.C., Gius D., Mitchell J.B. Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One 2009, 4:e6377.
72. Y. Wang, M.N. Scheiber, C. Neumann, G.A. Calin, D. Zhou, MicroRNA regulation of ionizing radiation-induced premature senescence, Int. J. Radiat. Oncol. Biol. Phys. 81 (3) (2011) 839-848.
73. M. Wagner-Ecker, C. Schwager, U. Wirkner, A. Abdollahi, P.E. Huber, MicroRNA expression after ionizing radiation in human endothelial cells, Radiat. Oncol. 5 (2010) 25.
74. F.F. Lan, H. Wang, Y.C. Chen, C.Y. Chan, S.S. Ng, K. Li, D. Xie, M.L. He, M.C. Lin, H.F. Kung, Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A), Int. J. Cancer 128 (2011) 319-331.
75. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318:1931-1934.
76. Vasudevan S., Tong Y., Steitz J.A. Cell-cycle control of microRNA-mediated translation regulation. Cell Cycle 2008, 7:1545-1549.
77. K. Breving, A. Esquela-Kerscher, The complexities of microRNA regulation: mirandering around the rules, Int. J. Biochem. Cell Biol. 42 (2010) 1316-1329.
78. Ding L.H., Shingyoji M., Chen F., Hwang J.J., Burma S., Lee C., Cheng J.F., Chen D.J. Gene expression profiles of normal human fibroblasts after exposure to ionizing radiation: a comparative study of low and high doses. Radiat. Res. 2005, 164:17-26.